Eli Lilly announced on " Good Morning America " Monday that its GLP-1 weight-loss drug Zepbound will now be available in a new multi-dose KwikPen, giving patients a simpler way to receive a full month ...
3don MSN
Lilly’s New Weight‑Loss Pill Shows Double the Results of Novo Nordisk’s GLP-1 Rival in a Major Study
Lilly’s new data show its oral GLP-1 beating Novo’s on major benchmarks.
5don MSN
Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen
Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.
Feb 26 (Reuters) - Eli Lilly's experimental weight-loss pill, orforglipron, caused more side effects and treatment ...
Eli Lilly and Company has reported detailed findings from the ACHIEVE-3 Phase III trial comparing the efficacy and safety of ...
The drugmaker unveiled a new Zepbound delivery system as its main rival absorbed fresh clinical and stock-market blows. It’s ...
LillyPod, which occupies 30,000 square feet in a room the size of a football field, is capable of crunching massive amounts of data at high speeds and is expected to help the Lilly discover and ...
Novo Nordisk’s post-trial sell-off may be overdone. Click here for this comparative analysis of NVO and LLY stocks and see ...
Eli Lilly released new data on its oral pill, orforglipron, Thursday, showing it's almost as good as Ozempic. The pill may be available this spring.
A local contractor is completing the buildout of a new manufacturing line in an existing Lilly building that focuses on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results